Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...
The Dow Jones Industrial Average reached a record high following a modest inflation report, spurring hopes for additional ...
U.S. stocks closed another record-setting week with a muted performance. The S&P 500 edged down by 0.1% Friday from its ...
The blue-chip Dow Jones Industrial Average closed at a record high today as investors welcomed a subdued inflation report ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...
The Dow Jones Industrial Average edged up to another record high while declines in tech stocks pulled other indexes lower.
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price ...
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback